PCOS Is Now PMOS: Why This One-Letter Change Could Transform Women’s Healthcare Globally

In today’s world, Polycystic Ovary Syndrome (PCOS) affects an estimated 10–13% of women globally, which translates to approximately 1 in every 8 to 10 women of reproductive age, or nearly 170 million women during their reproductive years. While many cases still go unnoticed, women have long complained of symptoms that extend far beyond what the term highlights: the “ovaries”. Core issues such as irregular periods, acne, excess hair growth, weight gain, insulin resistance, fertility concerns, mood changes, and mental health struggles often remained overlooked. But a couple of days ago, endocrinologists across the world celebrated. The reason? Only one letter had changed, but the impact was manifold.

On May 12, 2026, the Endocrine Society, a global network dedicated to hormone-related health, announced that PCOS (Polycystic Ovary Syndrome) would henceforth be known as PMOS (Polyendocrine Metabolic Ovarian Syndrome). This change follows over a decade of vigorous debate surrounding the need for a name that more accurately and comprehensively describes the condition. The revised name was introduced in a paper published in The Lancet and presented at the European Congress of Endocrinology in Prague. The paper argued that the term PCOS was “inaccurate” because it focused primarily on the presence of ovarian cysts, thereby overlooking the multitude of contributing factors, including diverse endocrine and metabolic features. The change carries particular significance for India, where experts estimate the prevalence of the condition to be between 16 and 18 per cent.

In India, nearly 1 in 5 women of reproductive age are affected by PMOS, a number significantly higher than the global average. Contrary to popular belief, this is not simply about a “bad” diet or lack of exercise. Increasingly, experts are pointing towards the invisible stressors modern bodies are constantly exposed to — from air pollution and chronic stress to long hours spent in traffic, microplastics in water, and contaminated food systems. All of these quietly impact hormones, metabolism, inflammation, and overall reproductive health.

The new name will gradually be introduced globally over the next three years. However, unlike PCOS, PMOS highlights the condition’s multisystem nature, including metabolic features such as obesity, dysglycaemia (abnormal blood sugar levels), Type 2 diabetes, hypertension, dyslipidemia (high levels of bad cholesterol and triglycerides), metabolic dysfunction-associated steatotic liver disease (MASLD) or fatty liver, cardiovascular disease, and sleep apnoea. It also addresses reproductive features that may manifest as ovulatory dysfunction, irregular menstrual cycles, infertility, pregnancy complications, and an increased risk of endometrial cancer. Psychological features include depression, anxiety, poor quality of life, and eating disorders, while dermatological symptoms include acne, scalp thinning, and facial hair growth.

“The renaming of PCOS to PMOS is more than a change in terminology; it is a correction in how we understand women’s health,” shared Dr Preeti Sharma, Senior Consultant – Obstetrics and Gynaecology, Cocoon Hospital, Jaipur. “For decades, the word ‘polycystic’ led many women to believe that ovarian cysts were central to the condition, while in reality, the disorder often reflects a much wider endocrine and metabolic imbalance. PMOS acknowledges that. This shift can help reduce delayed diagnosis, confusion, and stigma, and most importantly, it reminds us that women with this condition need long-term, personalised care.”

However, the name will not immediately change diagnostic criteria or treatment protocols. However, it may help women better understand the condition. It may also encourage clinicians to adopt a more comprehensive approach to patient care by placing greater emphasis on screening for blood sugar, cholesterol, blood pressure, and other long-term health risks, alongside lifestyle modification and multidisciplinary management, in addition to reproductive concerns.

Dr. Sharmishtha Mondal, Founder of Be.ing Painfree, says, “Language matters in healthcare. The way we name a condition shapes how seriously it is understood, researched, diagnosed, and treated — and that’s an important step forward for women’s healthcare. The term ‘metabolic’ in PMOS matters because it finally recognises the role of insulin, hormones, glucose, energy regulation, and overall metabolic health.”

In many ways, the shift from PCOS to PMOS is not just about changing a medical term, but about changing the conversation around women’s health itself. For years, countless women struggled with symptoms that felt disconnected, misunderstood, or dismissed because the name of the condition failed to capture its full complexity. By recognising PMOS as a multisystem disorder rather than simply an ovarian condition, the medical community is taking a significant step towards more accurate diagnosis, holistic treatment, and deeper awareness.

More importantly, the change also reflects a growing global acknowledgement that women’s health cannot continue to be reduced to isolated symptoms. PMOS opens the door to a broader, more informed understanding of how modern living impacts the female body. And perhaps, for millions of women navigating the condition silently, that recognition alone already feels like progress.